2021 SITC临床实践指南：肝细胞癌的免疫治疗

2021-09-10 肿瘤免疫治疗学会 J Immunother Cancer

2021年9月，肿瘤免疫治疗学会(SITC)发布了肝细胞癌的免疫治疗指南。

中文标题：

英文标题：

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma

发布机构：

肿瘤免疫治疗学会

发布日期：

2021-09-10

简要介绍：

2021年9月，肿瘤免疫治疗学会(SITC)发布了肝细胞癌的免疫治疗指南。肝细胞癌（HCC）患者在接受标准治疗的酪氨酸激酶（TKIs）后病情进展时预后极差。肝癌的标准治疗已经转为免疫检查点抑制剂（ICI）阿替利珠单抗加抗血管内皮因子（VEGF)抗体贝伐单抗被证实在一线治疗中可提高患者的总体生存率。本文主要针对肝细胞癌的免疫治疗提供指导建议。

相关资料下载：

GetToolGuiderByIdResponse(projectId=1, id=72a6f1c00218821d, title=2021 SITC临床实践指南：肝细胞癌的免疫治疗, enTitle=Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma, guiderFrom=J Immunother Cancer, authorId=0, author=, summary=2021年9月，肿瘤免疫治疗学会(SITC)发布了肝细胞癌的免疫治疗指南。, cover=https://img.medsci.cn/2021917/1631889593639_5579292.jpg, journalId=0, articlesId=null, associationId=1167, associationName=肿瘤免疫治疗学会, associationIntro=null, copyright=0, guiderPublishedTime=Fri Sep 10 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<p class="bold" style="color: #373737;">2021年9月，肿瘤免疫治疗学会(SITC)发布了肝细胞癌的免疫治疗指南。肝细胞癌（HCC）患者在接受标准治疗的酪氨酸激酶（TKIs）后病情进展时预后极差。肝癌的标准治疗已经转为免疫检查点抑制剂（ICI）阿替利珠单抗加抗血管内皮因子（VEGF)抗体贝伐单抗被证实在一线治疗中可提高患者的总体生存率。本文主要针对肝细胞癌的免疫治疗提供指导建议。</p>, tagList=[TagDto(tagId=357, tagName=肝细胞癌)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=357, guiderKeyword=肝细胞癌, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=2, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=3662, appHits=93, showAppHits=0, pcHits=592, showPcHits=3569, likes=1, shares=6, comments=6, approvalStatus=1, publishedTime=Sat Sep 18 20:55:32 CST 2021, publishedTimeString=2021-09-10, pcVisible=1, appVisible=1, editorId=5579292, editor=FUNNYMAN, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=FUNNYMAN, createdTime=Fri Sep 17 22:41:39 CST 2021, updatedBy=5579292, updatedName=FUNNYMAN, updatedTime=Mon Jan 01 10:40:13 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2021 SITC临床实践指南：肝细胞癌的免疫治疗.pdf)])

2021 SITC临床实践指南：肝细胞癌的免疫治疗.pdf

下载请点击：

评论区 (6)

#插入话题

插入图片

[GetPortalCommentsPageByObjectIdResponse(id=1186995, encodeId=4cf2118699538, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210826/7a6cce5e03844bcf8a6ee8a36dba8188/b15bf50504094d3aa56a8f1a32d3304c.jpg, createdBy=1d8c1533153, createdName=未来将来, createdTime=Fri Jan 21 22:01:25 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185026, encodeId=34111185026c3, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60261980226, createdName=1e17f66bm08(暂无匿称), createdTime=Mon Jan 17 00:20:28 CST 2022, time=2022-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1179366, encodeId=c3c611e93661d, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2f9b5676168, createdName=zhangfan5297, createdTime=Fri Dec 31 16:46:13 CST 2021, time=2021-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057484, encodeId=7482105e48450, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=887b5610574, createdName=ms1000002121020113, createdTime=Mon Oct 04 13:59:49 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057483, encodeId=b77c105e483eb, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=887b5610574, createdName=ms1000002121020113, createdTime=Mon Oct 04 13:59:31 CST 2021, time=2021-10-04, status=1, ipAttribution=)]
2022-01-21 未来将来

学习了

66 0
[GetPortalCommentsPageByObjectIdResponse(id=1186995, encodeId=4cf2118699538, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210826/7a6cce5e03844bcf8a6ee8a36dba8188/b15bf50504094d3aa56a8f1a32d3304c.jpg, createdBy=1d8c1533153, createdName=未来将来, createdTime=Fri Jan 21 22:01:25 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185026, encodeId=34111185026c3, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60261980226, createdName=1e17f66bm08(暂无匿称), createdTime=Mon Jan 17 00:20:28 CST 2022, time=2022-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1179366, encodeId=c3c611e93661d, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2f9b5676168, createdName=zhangfan5297, createdTime=Fri Dec 31 16:46:13 CST 2021, time=2021-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057484, encodeId=7482105e48450, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=887b5610574, createdName=ms1000002121020113, createdTime=Mon Oct 04 13:59:49 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057483, encodeId=b77c105e483eb, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=887b5610574, createdName=ms1000002121020113, createdTime=Mon Oct 04 13:59:31 CST 2021, time=2021-10-04, status=1, ipAttribution=)]
2022-01-17 1e17f66bm08(暂无匿称)

好

56 0
[GetPortalCommentsPageByObjectIdResponse(id=1186995, encodeId=4cf2118699538, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210826/7a6cce5e03844bcf8a6ee8a36dba8188/b15bf50504094d3aa56a8f1a32d3304c.jpg, createdBy=1d8c1533153, createdName=未来将来, createdTime=Fri Jan 21 22:01:25 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185026, encodeId=34111185026c3, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60261980226, createdName=1e17f66bm08(暂无匿称), createdTime=Mon Jan 17 00:20:28 CST 2022, time=2022-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1179366, encodeId=c3c611e93661d, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2f9b5676168, createdName=zhangfan5297, createdTime=Fri Dec 31 16:46:13 CST 2021, time=2021-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057484, encodeId=7482105e48450, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=887b5610574, createdName=ms1000002121020113, createdTime=Mon Oct 04 13:59:49 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057483, encodeId=b77c105e483eb, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=887b5610574, createdName=ms1000002121020113, createdTime=Mon Oct 04 13:59:31 CST 2021, time=2021-10-04, status=1, ipAttribution=)]
2021-12-31 zhangfan5297

很好

54 0
[GetPortalCommentsPageByObjectIdResponse(id=1186995, encodeId=4cf2118699538, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210826/7a6cce5e03844bcf8a6ee8a36dba8188/b15bf50504094d3aa56a8f1a32d3304c.jpg, createdBy=1d8c1533153, createdName=未来将来, createdTime=Fri Jan 21 22:01:25 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185026, encodeId=34111185026c3, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60261980226, createdName=1e17f66bm08(暂无匿称), createdTime=Mon Jan 17 00:20:28 CST 2022, time=2022-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1179366, encodeId=c3c611e93661d, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2f9b5676168, createdName=zhangfan5297, createdTime=Fri Dec 31 16:46:13 CST 2021, time=2021-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057484, encodeId=7482105e48450, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=887b5610574, createdName=ms1000002121020113, createdTime=Mon Oct 04 13:59:49 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057483, encodeId=b77c105e483eb, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=887b5610574, createdName=ms1000002121020113, createdTime=Mon Oct 04 13:59:31 CST 2021, time=2021-10-04, status=1, ipAttribution=)]
2021-10-04 ms1000002121020113

不错

80 0
[GetPortalCommentsPageByObjectIdResponse(id=1186995, encodeId=4cf2118699538, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210826/7a6cce5e03844bcf8a6ee8a36dba8188/b15bf50504094d3aa56a8f1a32d3304c.jpg, createdBy=1d8c1533153, createdName=未来将来, createdTime=Fri Jan 21 22:01:25 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185026, encodeId=34111185026c3, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60261980226, createdName=1e17f66bm08(暂无匿称), createdTime=Mon Jan 17 00:20:28 CST 2022, time=2022-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1179366, encodeId=c3c611e93661d, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2f9b5676168, createdName=zhangfan5297, createdTime=Fri Dec 31 16:46:13 CST 2021, time=2021-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057484, encodeId=7482105e48450, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=887b5610574, createdName=ms1000002121020113, createdTime=Mon Oct 04 13:59:49 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057483, encodeId=b77c105e483eb, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=887b5610574, createdName=ms1000002121020113, createdTime=Mon Oct 04 13:59:31 CST 2021, time=2021-10-04, status=1, ipAttribution=)]
2021-10-04 ms1000002121020113

好

74 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

肿瘤科指南

2021 SITC临床实践指南：肝细胞癌的免疫治疗

相关指南

拓展阅读

科室

工具

服务